Comparison of methotrexate and azathioprine in the treatment of psoriasis: a randomized controlled trial
DOI:
https://doi.org/10.66344/jpad.v20i3.409Abstract
Background Treatment of psoriasis requires a safe and effective drug which can be used on long term basis. Azathioprine is one such agent which was used in the past but has not been tested recently.
Patients and methods A randomized controlled trial was conducted at dermatology department, Combined Military Hospital, Kharian, to compare the efficacy and safety of azathioprine with that of methotrexate in patients with severe psoriasis requiring systemic therapy. Patients included in the study were randomized into two groups. Group A received tablet methotrexate 10 mg weekly for 8 weeks. Group B patients received tablet azathioprine in a dose of 1.5-3 mg/kg/day. In all the adult patients who were weighing more than 50 kg azathioprine was started at a dose of 50 mg tablet thrice daily for 8 weeks. PASI score was assessed at the start and end of treatment. Scores were compared in the two groups before and after and statistically analyzed using paired and independent sample t test.
Results 50 patients entered the study. Results were stratified into excellent, good, and poor response, based on improvement in PASI scores. Excellent response was seen in 73% patients in group A and 27% patients in group B (p<0.5). Good response was seen in 45% patients in group A and 55% patients in group B (p>0.5). Poor response was seen in one patient in each group (p>0.5, paired sample t test).
Conclusion Azathioprine is less effective in systemic treatment of psoriasis. Nevertheless it can be a useful alternative in selected patients.
References
1. Menter A, Korman N, Elmets C et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol 2010; 62: 114-35.
2. Nickoloff BJ. Cracking the cytokine code in psoriasis. Nat Med 2007; 13: 242-4.
3. Spuls PI, Witkamp L, Bossuyt PM, Bos JD. A systematic review of five systemic treatments for severe psoriasis. Br J Dermatol 1997; 137: 943-9.
4. Boztepe G, Karaduman A, Sahin S et al. The effect of maintenance narrow-band ultraviolet B therapy on the duration of remission for psoriasis: a prospective randomized clinical trial. Int J Dermatol 2006; 45: 245-50.
5. Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005; 44: 355-60.
6. Kampitak T, Asawanonda P. The efficacy of combination treatment with narrowband UVB (TL-01) and acitretin vs narrowband UVB alone in plaque-type psoriasis: a retrospective study. J Med Assoc Thai 2006; 89 (Suppl): S20–S24.
7. Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of plaque-type psoriasis: a randomized, placebo-controlled study. J Am Acad Dermatol 2006; 54: 1013-8.
8. Calzavara-Pinton P, Leone G, Venturini M et al. A comparative non randomized study of narrow-band (NB) (312 +/- 2 nm) UVB phototherapy versus sequential therapy with oral administration of low-dose cyclosporin A and NB-UVB phototherapy in patients with severe psoriasis vulgaris. Eur J Dermatol 2005; 15: 470-3.
9. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: The past, the present, and the future. J Am Acad Dermatol 2006; 55: 390-1.
10. Wolverton SE. Optimizing clinical use of azathioprine with newer pharmacogenetic data. Arch Dermatol 2009; 145: 707-10.
11. Greaves MW, Dawber W. Azathioprine in psoriasis. Br Med J 1970; 2 (5703): 237-8.
12. Mezzadra G. Therapeutic experience with azathioprine in psoriasis. G Ital Dermatol Minerva Dermatol 1972; 47: 72-6.
13. Du Vivier A, Munro DD, Verbov J. Treatment of psoriasis with azathioprine. Br Med J 1974; 1(5897): 49-51.
14. Saway PA, Heck LW, Bonner JR et al. Azathioprine efficacy and/or side effects of azathioprine therapy in dermatologic patients. Arch Dermatol 1995; 131: 193-5.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Tariq Malik, Amer Ejaz
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
